ResMed Adopts New Operating Model to Accelerate Long-term …
WEBSAN DIEGO, November 9, 2023 – ResMed (NYSE: RMD, ASX: RMD) today announced a new operating model to accelerate long-term growth. The new operating model introduces dedicated leadership in Product, Revenue, and Marketing to the global executive team.
ResMed Inc. (RMD) Latest Stock News & Headlines - Yahoo …
WEBGet the latest ResMed Inc. (RMD) stock news and headlines to help you in your trading and investing decisions.
Resmed Stock Poised for Growth: Buy Rating Affirmed Amid …
WEBApr 17, 2024 · In a report released today, Lyanne Harrison from Bank of America Securities reiterated a Buy rating on Resmed (RMD – Research Report), with a price target of $220.00.
Newsroom | Resmed Inc
WEBAug 1, 2024 · At ResMed we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases.
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal …
WEBSAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2024. Fourth Quarter 2024 Highlights. All comparisons are to the prior year period. Revenue increased by 9% to $1.2 billion; up 10% on a constant currency basis.
ResMed Adopts New Operating Model to Accelerate Long-term …
WEBSAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced a new operating model to accelerate long-term growth. The new operating model introduces dedicated...
ResMed Inc. Announces Results for the Second Quarter of Fiscal …
WEBSAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2022. Second Quarter 2023 Highlights. All comparisons are...
Why ResMed's Rally Is Just Getting Started - Seeking Alpha
WEB4 days ago · The good news for ResMed is that GLP-1 drugs are no risk. Even better, ResMed's products improve patient outcomes! According to the company, which cites a SURMOUNT-OSA study, patients with GLP-1 ...
ResMed Adopts New Operating Model to Accelerate Long-term …
WEBSAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced a new operating model to accelerate long-term growth. The new operating model introduces dedicated...
News | Resmed Inc
WEBMedia Contact. news@resmed.com. 1.858.289.7272. Investor Contact. investorrelations@resmed.com. 1.858.836.5000. Newsroom Alerts. To opt-in for email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an …
Skip to content